We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Patent Outlook Improving, Experts Say at MDMA

Patent Outlook Improving, Experts Say at MDMA

May 8, 2015

Patent troll cases filed against devicemakers have dropped dramatically in the wake of recent legal challenges, an attorney says.

Stephen Jensen, a partner with Knobbe, Martens, Olson and Bear, says patent law case filings have dropped from about 700 per month at their peak in 2012 to roughly 300 a month now, mostly due to recent U.S. Supreme Court rulings and legal changes. For example, a legal requirement that patent trolls file each case individually stops them from issuing claims against several dozen patent-holders at the same time, Jensen told attendees at the Medical Device Manufacturers Association annual meeting in Washington, D.C.

Further, of 119 cases where patent holders have asked to be reimbursed court costs, they were successful 58 times. Previously, “that would have been zero,” Jensen says.

Recent U.S. Patent and Trademark Office trends, such as an increase in inter partes review cases, 68 percent of which go to trial, also favor innovators, Jensen says. More than a third of patents reviewed through this process are found to be unenforceable, yet legal fees can exceed $100,000.

Currently, the Federal Circuit is reviewing a case, Lexmark International v. Impression Products, which questions whether use restrictions on product packaging are enough to prevent other manufacturers from making generic accessories for the products. The court has asked for amicus briefs on the question, Jensen says.

Since the Supreme Court’s Alice Corp. v. CLS Bank decision in 2014 made it harder to patent steps in a process, 76 of 99 cases on similar issues that went to trial resulted in the patent being struck down, Jensen adds. Another important case for devicemakers, Nautilus Inc. v. Biosig Instruments Inc., says patents have to be specific to apply. Previously, patents could be held valid as long as they were not “insolubly ambiguous,” Jensen says.

According to Angela Sykes, director of USPTO’s technology center, the agency issued 14,000 medical device patents in 2014, more than double the historic average. The agency established a new Office of Patent Training to bring examiners on up to speed on current patent issues, including patent subject matter eligibility. — Elizabeth Orr

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing